INTRODUCTION Obesity is represented mainly by abdominal obesity and insulin resistance (IR), both present in most individuals diagnosed with metabolic syndrome (MS). IR is the key risk factor in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Objective. To relate NAFLD to MS in class III obese individuals. METHODOLOGY A descriptive cross-sectional study with class III obese indi...

INTRODUCTION Metabolic syndrome (MS) has a high prevalence in hemodialysis' patients and is a risk factor for cardiovascular disease, the leading cause of mortality in chronic kidney disease (CKD). Objectives To evaluate the prevalence of MS in patients on hemodialysis (HD) and the difference in its prevalence according to the NCEP-ATP III and IDF criteria. METHODS We evaluated HD patients in...

T he Third Report of the National Cholesterol Education ProgramAdult Treatment Panel (NCEPATP III) and the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice recommended a low-density lipoprotein cholesterol (LDL-C) target of <100 mg/dl for patients with coronary heart disease (CHD). Indeed, the GREek Atorvastatin and Coronary heart ...

C oronary artery disease is estimated to affect over 81 million adults in America, with a projected cost of $156.4 billion healthcare dollars in 2008. It remains the leading cause of death in Americans, with an average of one death per minute due to a coronary event. Ninety percent of all persons with an acute coronary event will have at least one of the following predisposing risk factors: hyp...

OBJECTIVES Quantifying the risk of cardiovascular disease (CVD) in a community is important in planning preventive strategies, but such data are limited from developing countries, especially South Asia. We aimed to estimate the risks of coronary heart disease (CHD), total CVD, and CVD mortality in a Sri Lankan community. METHODS A community survey was conducted in an urban health administrati...

AIM The objective of the article is the evaluation of prevalence of the metabolic syndrome--MS and its components in EUFEST research amongst subjects with Polish nationality. MATERIAL The studied group consisted of 94 patients, aged from 18-40, with the first episode of schizophrenia, schizophreniform or schizoaffective disorders (DSM-IV) never treated with antipsychotics or not longer than f...

BACKGROUND & OBJECTIVE The identification of metabolic syndrome (MS) among patients with type 2 diabetes (T2DM) is of great importance, since those with MS carry a cluster of cardiovascular risk factors. This study evaluates suitable criteria with high efficiency in diagnosing MS and to identify the strongest predictors of MS in newly detected type 2 diabetes individuals. METHODS Newly detect...